|Videos|January 9, 2023
Managing Toxicities with Tucatinib in Patients with HER2+ mCRC
Deanna Griffie, MSN, AGNP-BC, and Tanios Bekaii-Saab, MD, explain how they manage the toxicities of tucatinib in patients with HER2+ mCRC, and how they educate patients on what to expect.
Advertisement
Episodes in this series
Advertisement
Related to this article
The FDA approved adjuvant atezolizumab with chemotherapy for patients with resected stage III dMMR colon cancer based on results from the phase 3 ATOMIC trial.
Advertisement
Advertisement
Trending on CancerNetwork
1
Sequencing Bispecifics and CAR T-Cell Therapy in Myeloma and AL Amyloidosis
2
Larger Prostates Showed Post-Radiotherapy Urinary Symptom Normalization
3
Weighing the Promise and Trade-offs of CAR NK Cell Therapy for Cancer
4
Building a Low-Dose Radiation Therapy Program for Benign Disease
5